HD-003 / Hyundai Pharm - LARVOL DELTA

Comparison of Methods for Site Harmonization Using PTSD as a Test Case (SOBP 2023) - "Davidson); core grant to the Waisman Center from the National Institute of Child Health and Human Development (P30-HD003352); NIMH K23MH112873; Veterans Affairs Merit Review Program (10/01/08 – 09/30/13); L30 MH114379; South African Medical Research Council “SHARED ROOTS” Flagship Project; Grant -RFA-FSP-01-2013/SHARED ROOTS; South African Research Chair in PTSD from the Department of Science and Technology and the National Research Foundation; US Department of Defense Grant W81XWH08-2-0159 (PI: Stein, Murray B); VA RR&D I01RX000622; CDMRP W81XWH-08-2-0038; South African Medical Research Council; NARSAD Young Investigator; Department of Defense award number W81XWH-12-2-0012; ENIGMA was also supported in part by U54 EB020403 from the Big Data to Knowledge (BD2K) program; R56AG058854; R01MH116147;; P41 EB015922; 1R01MH110483; 1R21 MH098198; R01MH105355-01A...Both ComBat and ComBat-GAM outperformed LME methods in detecting sex differences (Χ2(3) = 9.114, p = 0.028) in..."

Clinical • Harmonization • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder • ID3

Change From Baseline to Chronic Kidney Disease Patient Before and After Administration Drug (clinicaltrials.gov) - P2; N=62; Completed; Sponsor: Hyundai Pharmaceutical Co., LTD.

New P2 trial • Biosimilar • Chronic Kidney Disease • Growth Hormone • Immunology • Inflammation • Renal Disease